Revvity has entered into a definitive agreement to acquire Human Cell Design, adding human pancreatic beta cell models and other preclinical research technologies focused on diabetes, obesity and metabolic diseases.
Human Cell Design, or HCD, is a France-based biotechnology company specializing in human cell models and preclinical research solutions. The acquisition is expected to expand Revvity’s capabilities for drug discovery, screening and preclinical research, including next-generation GLP-1 and other metabolic disease therapies.
Financial terms were not disclosed. The transaction is expected to close in the fourth quarter of 2026, subject to customary closing conditions and required regulatory approvals.
HCD’s flagship product is EndoC-βH5, a human pancreatic beta cell model designed to help researchers study beta cell physiology and function in diabetes and obesity research.
HCD also provides specialized media and reagents, preclinical research services and NatLine, its proprietary cell-line development platform for producing functionally consistent human cell models.
Revvity plans to combine those capabilities with its existing technologies for cell analysis, detection, high-content screening, gene editing and automation.
HCD’s EndoC-βH5 cells can be used with Revvity technologies including HTRF and AlphaLISA assays to measure pharmacological readouts such as cAMP and insulin, pHSense technology for receptor internalization studies, and ATPlite assays for cell viability and proliferation.
The acquisition also reflects growing demand for biological models that more closely represent human physiology as pharmaceutical and biotechnology companies increasingly combine traditional laboratory research with AI-powered drug discovery.
Revvity noted that human-relevant cell models can provide an important wet-lab validation layer for testing and confirming insights generated through AI-enhanced scientific research.
HCD’s technologies may also have applications beyond early drug discovery. The company has been involved in research supporting regenerative medicine for Type 1 diabetes and quality-control activities as cell-based therapies move closer to commercialization.
Revvity generated $2.9 billion of revenue in 2025, employs approximately 11,000 people and serves customers across pharmaceutical and biotechnology companies, diagnostic laboratories, academia and governments in more than 160 countries.
KEY QUOTES:
“HCD brings differentiated human cell models that complement Revvity’s broad portfolio of technologies supporting drug discovery and development,” said Prahlad Singh, president and CEO of Revvity. “As researchers continue to seek more human-relevant approaches to understanding biology, combining high-quality cell models with our capabilities in screening, detection, automation and analysis creates an opportunity to provide customers with more integrated solutions.”
Prahlad Singh, President and CEO of Revvity
“Human Cell Design was founded on the belief that better human models can help transform the way medicines are discovered and developed,” said Guillaume Costecalde, founder and president of Human Cell Design. “Joining Revvity is expected to allow us to bring our human cell models and NatLine technology to a broader global customer base while supporting the development of new physiologically relevant cell models.”
Guillaume Costecalde, Founder and President of Human Cell Design
